qXR-CTR vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

qXR-CTR

by Qure.ai Technologies

EchoNext

by Pathway Labs

AI Verdict

Both qXR-CTR and EchoNext are AI tools focused on cardiac health assessment and are FDA-cleared and HIPAA compliant. However, qXR-CTR specializes in analyzing chest X-rays to measure cardiothoracic ratio for heart size assessment, while EchoNext analyzes ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. Therefore, the choice between them depends on whether the primary diagnostic input is chest X-ray or ECG data.

Choose qXR-CTR if…

Choose qXR-CTR if your primary need is automated, precise measurement of the cardiothoracic ratio (CTR) from chest X-ray images to assess heart size and screen for potential heart failure risk. This tool is ideal for radiology departments and clinics seeking to enhance the accuracy and efficiency of cardiomegaly diagnosis and facilitate earlier detection of heart failure using existing chest X-ray infrastructure.

View qXR-CTR →

Choose EchoNext if…

Choose EchoNext if you require an AI-powered solution to analyze standard ECGs for the detection of hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. This tool is best suited for broad screening in various clinical settings, from major hospitals to community practices, aiming to identify patients who may need further evaluation with an echocardiogram, especially when early, non-invasive detection of complex heart conditions is critical.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	qXR-CTR	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Cloud, on-premise, hybrid	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

EchoNext

EchoNext is designed for broad access and is available through the OpenEvidence clinical decision support platform, which is used by over half a million U.S. physicians. This integration into an existing workflow suggests a higher degree of immediate usability and accessibility for a large user base. qXR-CTR is deployed via cloud, on-premise, or hybrid, and while flexible, its user experience details are not as explicitly highlighted as EchoNext's integration into a widely used platform.

Clinical Value

EchoNext

EchoNext has demonstrated superior diagnostic accuracy compared to cardiologists in identifying structural heart problems, with 77% accuracy versus 64% for cardiologists. It detects six conditions, including heart failure, valve disease, and pulmonary hypertension, from a standard ECG, which traditionally cannot detect structural heart disease. qXR-CTR automates CTR measurement from chest X-rays to assess heart size and heart failure risk, and while valuable, its reported accuracy and breadth of detected conditions are not as extensively detailed or compared against expert performance in the provided information.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, with details on different plans, implementation fees, and discounts. This transparency allows potential users to better assess the value proposition. qXR-CTR's pricing is not publicly disclosed, requiring direct contact for information, which makes a direct comparison of value difficult.

Enterprise Readiness

EchoNext

EchoNext is designed for broad access, from major hospitals to community practices, and is available through the OpenEvidence clinical decision support platform, used by over 500,000 U.S. physicians. This wide distribution and integration indicate strong enterprise readiness. qXR-CTR offers cloud, on-premise, and hybrid deployment options, suggesting flexibility, but lacks specific details on its current enterprise adoption or integration with widely used platforms.

Innovation

EchoNext

EchoNext is highlighted as the world's first FDA-cleared AI tool to detect hidden structural heart disease from standard ECGs, a test traditionally unable to do so. This represents a significant innovative leap in early detection. qXR-CTR automates CTR measurement from chest X-rays, which is an advancement, but EchoNext's ability to extract structural heart disease information from a routine ECG is a more novel application of AI in cardiology.

Support & Docs

Tie

Neither the provided structured facts nor the web search results offer specific details regarding the level of customer support, training, or documentation available for either qXR-CTR or EchoNext. Therefore, it is not possible to definitively pick a winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	qXR-CTR	EchoNext
Name	qXR-CTR	EchoNext
Company	Qure.ai Technologies	Pathway Labs
Description	AI-powered software that automates the measurement of the cardiothoracic ratio (CTR) from chest X-ray images, aiding in the assessment of heart size and potential heart failure risk.	FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Categories	Cardiology AI, Radiology & Imaging AI	Cardiology AI, Clinical Decision Support & Reference, Lab & Diagnostics
Specialties	Cardiology, Radiology	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine
Key Features	Not specified	AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support

Videos

Demos, reviews, and walkthroughs featuring qXR-CTR and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

qXR-CTR is designed to integrate into the existing standard of care workflow and acts as a passive notification system for worklist prioritization. EchoNext integrates with the OpenEvidence clinical decision support platform, which is used by many physicians, allowing its screening output to be directly accessible within a tool many physicians already use during patient visits, rather than requiring a separate workflow or system.

What is the accuracy and sensitivity of each tool in detecting cardiac conditions?

qXR-CTR has demonstrated high sensitivity (96.88%) and an AUC of 91.92% in identifying abnormal chest X-rays, with a high negative predictive value of 99.43% for normal CXRs. EchoNext achieved an AUROC of 85.2% in internal tests and 78-80% in external validation for detecting structural heart disease, outperforming cardiologists who achieved 64% accuracy (77% for AI alone).

For which specific cardiac specialties and conditions are these tools best suited?

qXR-CTR is primarily suited for cardiology and radiology, specifically for automating the measurement of the cardiothoracic ratio from chest X-rays to aid in assessing heart size and potential heart failure risk. EchoNext is designed for cardiology, family medicine, hospital medicine, and internal medicine, focusing on analyzing standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, severe hypertrophy, and pulmonary hypertension.

What is the typical learning curve for physicians to effectively use each tool?

qXR-CTR is a deep-learning based software designed for automated assessment of CTR on chest X-rays, suggesting a relatively straightforward learning curve for interpreting its output. EchoNext analyzes standard ECGs and provides risk scores, and while it outperforms cardiologists, the integration with a platform like OpenEvidence aims to make it readily accessible within existing physician workflows, potentially reducing the learning curve for adoption.

What kind of customer support and resources are available for ongoing use and troubleshooting?

While specific details on support quality are not provided, Qure.ai is a global innovator in radiology AI solutions, suggesting a commitment to supporting their products. Pathway Labs has partnered with OpenEvidence to expand access to EchoNext, implying a support structure through this platform.

What are the audit-trail features of each tool, and how do they support clinical accountability?

The provided information does not explicitly detail the audit-trail features for either qXR-CTR or EchoNext. However, as medical devices, both would be expected to maintain appropriate records for clinical accountability.

What clinical context should physicians consider when choosing between qXR-CTR and EchoNext?

Physicians should consider that qXR-CTR focuses on automated cardiothoracic ratio measurement from chest X-rays, aiding in heart size assessment and heart failure risk, and its results are not intended for stand-alone clinical decision-making. EchoNext, on the other hand, analyzes standard ECGs to detect a broader range of hidden structural heart diseases, including heart failure, valve disease, and pulmonary hypertension, and has shown to identify conditions cardiologists might miss from ECGs alone.